Zimmer Biomet (NYSE:ZBH) is scheduled to release its earnings data on Monday, January 29th. Zimmer Biomet has set its Q4 guidance at $2.08-$2.14 EPS and its FY17 guidance at $8.01-$8.07 EPS.
Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The business had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The business’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the company posted $1.79 earnings per share. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.
Zimmer Biomet (ZBH) opened at $123.48 on Monday. The stock has a market capitalization of $25,001.37, a P/E ratio of 38.83, a PEG ratio of 1.92 and a beta of 1.15. Zimmer Biomet has a one year low of $108.03 and a one year high of $133.49. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.
ZBH has been the topic of a number of research reports. Deutsche Bank upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a report on Tuesday, November 14th. Edward Jones upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. SunTrust Banks set a $136.00 price target on Zimmer Biomet and gave the stock a “buy” rating in a report on Wednesday, November 1st. Jefferies Group restated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a report on Friday, November 3rd. Finally, BMO Capital Markets restated a “buy” rating and issued a $142.00 price target on shares of Zimmer Biomet in a report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $137.42.
TRADEMARK VIOLATION NOTICE: “Zimmer Biomet (ZBH) to Release Earnings on Monday” was published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/22/zimmer-biomet-zbh-to-release-earnings-on-monday.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.